GSK and Empirico Collaborate on Oligonucleotide Candidate
GSK plc and Empirico Inc. have entered into a worldwide exclusive license agreement for EMP-012, a highly selective siRNA oligonucleotide.
EMP-012 addresses a novel therapeutic target and is currently in a phase I trial for the treatment of chronic obstructive pulmonary disease (COPD), with potential expansion into other inflammatory respiratory diseases.
Medical need in COPD remains high despite ongoing innovation.
Author's summary: GSK and Empirico collaborate on siRNA oligonucleotide for respiratory diseases.
More News
- Fashion lovers step out for Carol Byrne X Very Partywear Edit
- Thailand's 'new Chinatowns' bring in the wrong type of investment
- Selling Sunset: Has Nicole been fired? Fans left cringing at ‘horrendous’ remark
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Austin Reaves cracks viral joke after buzzer-beater lifts Lakers to win